placeholder

Publications

In recent years, the Lu Lab has published research in a variety of academic journals as corresponding author, including the Journal of Clinical Investigation, Nature Communications. Please see a featured selection of publications below.

 

PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma

Mondal I, Das O, Sun R, Gao J, Yu B, Diaz A,  Behnan J, Dubey A, Meng Z, Eskandar E, Xu B, Lu R*, and Ho W* corresponding author 

Cancer Research. 2023 Aug 1; 83 (15): 2527-2542. doi: 10.1158/0008-5472.CAN-22-3382. In press.
PubMed Link >

PP2A/STRN4 Negatively Regulates STING-Type I Interferon Signaling in Tumor Associated Macrophages

Ho WS*, Mondal I*, Xu B*, Das O*, Sun R, Chiou P, Lyu J, Li L, Cai X, Tahmasebinia F,  Wu C Y-J, Wu Z, Matsui W, Lim M, Meng Z, Lu RO* corresponding author 

J Clin Invest. 2023 Mar 15; 133 (6): e162139. doi: 10.1172/JCI162139. In press.
PubMed Link >

Mitochondrial Dysfunction, Macrophage, and Microglia in Brain Cancer

Lu R* Ho W

Front Cell Dev Bio. 2021 Jan 15; 8: 620788. doi: 10.3389/fcell.2020.620788.
PubMed Link >

Inhibition of protein phosphatase-2A with PD-1 blockade enhances antitumor immunity and survival in glioblastoma

Maggio D, Ho WS, Breese R, Walbridge S, Wang H, Heiss JD, Gilbert MR,Kovach JS, Lu R*, Zhuang Z corresponding author 

J Neurooncol. 2020 Jun 1; 148 (2): 231-244. doi: 10.1007/s11060-020-03517-5.
PubMed Link >

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R*, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM co-first author

J Immunother Cancer. 2019 May 22; 7 (1): 131. doi: 10.1186/s40425-019-0602-4.
PubMed Link >

Pharmacological inhibition of protein phosphatase-2A, with novel inhibitor LB-100, achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

Ho W, Wang H, Heiss J, Gilbert MR, Lu R* corresponding author

Nat Commun. 2018 May 29; 9 (1): 2126. doi: 10.1038/s41467-018-04425-z.
PubMed Link >

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

Danaher P, Warren S, Lu R, Sullivan A, Samayoa J, Marincola F, Pekker I, Wallden B, Cesano A

J Immunother Cancer. 2018 Jun 22; 6 (1): 63. doi: 10.1186/s40425-018-0367-1.
PubMed Link >

Immune Oncology, Immune Responsiveness and the Theory of Everything

Turan T, Kannan D, Patel M, Barnes JM, Tanlimco S, Lu R, Halliwill K, Kongpachith S, Kline D, Hendrickx W, Cesano A, Butterfield LH, Kauffman H, Hudson T, Bedognetti D, Marincola F, Samayoa J

J Immunotherapy Cancer. 2018 Jun 5; 6 (50): doi: 10.1186/s40425-018-0355-5.
PubMed Link >

LB-100, a novel Protein Phosphatase 2A Inhibitor (PP2A), Sensitizes Malignant Meningioma Cells to the Therapeutic Effects of Radiation

Ho W, Sizdahkhani S, Hao S, Song H , Seldomridge A, Tandle A, Maric D, Kramp T, Lu R , Heiss J, Camphausen K , Gilbert MR , Zhuang Z , Deric M. Park

Cancer Lett. 2018 Feb 28; 6 (1): 217-226. doi: 10.1016/j.canlet.2017.11.035.
PubMed Link >

Cancer Immune Resistance: Can Theories Converge?

Lu R*, Turan T, Samayoa J, Marincola FM

Emerg Top Life Sci. 2017 Dec 12; 1 (5): 411-19. doi: 10.1042/ETLS20170060.
PubMed Link >

Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells

Rutz S, Kayagaki N, Phung QT, Eidenschenk C, Noubade R, Lesch J, Lu R, Newton K, Huang OW,Cochran AG, DeVoss J, Webster J, Diehl L, Kirkpatrick DS, Lill JR, Ouyang W, Dixit VM

Nature. 2015 Feb 19; 518 (7539): 417-21. doi: 10.1038/nature13979.
PubMed Link >

NRROS negatively regulates the production of reactive oxygen species in phagocytes during host defense and autoimmunity

Noubade R, Wong K, Ota N, Rutz S, Eidenschenk C, Valdez PA, Ding J, Peng I, Sebrell A, Caplazi P, DeVoss J, Soriano RH, Sai T, Lu R, Modrusan Z, Hackney J, Ouyang W

Nature. 2014 May 8; 509 (7499): 235-9. doi: 10.1038/nature13152.
PubMed Link >

STAT3 activation in tumor cell-free lymph nodes predicts a poor prognosis for gastric cancer

Wu L, Li H, Luo X, Lu R, Ma Y, Wang R, Zhang, J, Yu H, Liu J

Int J Clin Exp Pathol. 2014 Feb 15; 7 (3): 1140-6.
PubMed Link >

G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells

Xin H, Lu R, Lee H, Zhang W, Zhang C, Deng J, Liu Y, Shen S, Wagner KU, Forman S, Jove R, Yu H.

J Biol Chem. 2013 May 10; 288 (19): 13842-9. doi: 10.1074/jbc.M113.450049.
PubMed Link >

CEACAM1 negatively regulates IL-1β production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex

Lu R, Pan H, Shively JE

PLoS Pathog. 2012 Apr 5; 8 (4): doi: 10.1371/journal.ppat.100259.
PubMed Link >